Statistics for Trial in progress update on ENGOT-cx8/GOG-3024/innovaTV 205: Addition of a new cohort with first-line (1L) tisotumab vedotin (TV) plus pembrolizumab (pembro) plus carboplatin (carbo) +/- bevacizumab (bev) in recurrent/metastatic cervical cancer (r/mCC)
Total visits
| views | |
|---|---|
| Trial in progress update on ENGOT-cx8/GOG-3024/innovaTV 205: Addition of a new cohort with first-line (1L) tisotumab vedotin (TV) plus pembrolizumab (pembro) plus carboplatin (carbo) +/- bevacizumab (bev) in recurrent/metastatic cervical cancer (r/mCC) | 0 |
Total visits per month
| views | |
|---|---|
| August 2024 | 0 |
| September 2024 | 0 |
| October 2024 | 0 |
| November 2024 | 0 |
| December 2024 | 0 |
| January 2025 | 0 |
| February 2025 | 0 |